Yutaka Kawakami

Keio University, Minato-ku, Tōkyō-to, Japan 
"Yutaka Kawakami"
Mean distance: 16.96 (cluster 17)


Sign in to add trainee
Yohei Ohashi research assistant 2000-2004 Keio University
Yukihiko Iizuka grad student 1999-2004 Keio University
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hirao N, Iwata T, Tanaka K, et al. (2019) Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter. Gynecologic Oncology
Kikuchi R, Ueda R, Saito K, et al. (2019) A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma. Journal of Clinical Medicine. 8
Mukai S, Ogawa Y, Saya H, et al. (2018) Therapeutic potential of tranilast for the treatment of chronic graft-versus-host disease in mice. Plos One. 13: e0203742
Shibao S, Ueda R, Saito K, et al. (2018) A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma. Oncotarget. 9: 21569-21579
Kamamoto D, Ohara K, Kitamura Y, et al. (2018) Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. Journal of Neuro-Oncology
Nakamura K, Yaguchi T, Ohmura G, et al. (2017) Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment. Cancer Science
Ohta S, Kawakami Y, Okano H. (2017) MIF: functions in brain and glioblastoma. Oncotarget
Saito K, Ohta S, Kawakami Y, et al. (2017) Functional analysis of KIF20A, a potential immunotherapeutic target for glioma. Journal of Neuro-Oncology
Ohta S, Yaguchi T, Okuno H, et al. (2016) CHD7 promotes proliferation of neural stem cells mediated by MIF. Molecular Brain. 9: 96
Fukaya R, Ohta S, Yaguchi T, et al. (2016) MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53. Cancer Research
See more...